Search Within

Matthew J Matasar

Formats
  1. Meeting Abstract (192)
  2. Journal Article (86)
  3. Book Section (4)
  4. Review (3)
  5. Correspondence (2)
  6. Editorial (2)
  7. Research Letter (2)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (293)
  2. Department of Medicine (293)
  3. Hematologic Malignancies, Division of (293)
  4. Lymphoma (293)
  5. Survivorship Research (293)
  6. Population Sciences Research Program (113)

More Groups

People
  1. Andrew Zelenetz (118)
  2. David Straus (104)
  3. Ariela Noy (101)
  4. Paul Hamlin (100)
  5. Steven Horwitz (98)
  6. Alison Moskowitz (96)

More People

Years
  1. 2024 (9)
  2. 2023 (12)
  3. 2022 (43)
  4. 2021 (43)
  5. 2020 (23)
  6. 2019 (34)

More Years

Publications
  1. Blood (110)
  2. Journal of Clinical Oncology (37)
  3. Hematological Oncology (22)
  4. Biology of Blood and Marrow Transplantation (11)
  5. Clinical Lymphoma, Myeloma and Leukemia (11)
  6. Blood Advances (10)

More Publications

Publishers
  1. American Society of Hematology (120)
  2. American Society of Clinical Oncology (37)
  3. Elsevier Inc. (29)
  4. Wiley Blackwell (26)
  5. Oxford University Press (13)
  6. John Wiley & Sons (10)

More Publishers

Results (293)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PI3K inhibitors in haematological malignancies
    Correspondence

    Matasar, M. J.; Hiemeyer, F.; Childs, B. H.; Zinzani, P. L.
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphoma
    Meeting Abstract

    Dahi, P. B.; Geyer, A.; Kenny, S.; Flynn, J.; Devlin, S. M.; Ruiz, J. D.; Lahoud, O. B.; Matasar, M. J.; Moskowitz, C. H.; Perales, M. A.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study
    Journal Article

    Budde, L. E.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory follicular lymphoma who have received ≥ 2 prior lines of therapy: Pivotal results from a phase I/II study
    Meeting Abstract

    Budde, E.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma: Results from the phase III POLARIX study
    Meeting Abstract

    Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný, M.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; Matasar, M.; Rai, S.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma
    Journal Article

    Lin, R. J.; Owens, C. N.; Drill, E.; Iannotta, A.; Oliveros, M.; Schick, D. L.; Noy, A.; Gerecitano, J. F.; Drullinsky, P. R.; Caron, P. C.; more...
    Haematologica (2022)

    Fulltext@MSK | Save
  • Reaching beyond maximum grade: Progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies
    Review

    Thanarajasingam, G.; Minasian, L. M.; Bhatnagar, V.; Cavalli, F.; De Claro, R. A.; Dueck, A. C.; El-Galaly, T. C.; Everest, N.; Geissler, J.; Gisselbrecht, C.; more...
    The Lancet Haematology (2022)

    Fulltext@MSK | Save
  • Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: A single-center experience
    Journal Article

    Pak, T. K.; Dixon, B. N.; Buege, M. J.; Dao, P. H.; Leary, M. H.; Jarrett, J. C.; Duggan, T. A.; Caron, P.; Falchi, L.; Hamlin, P.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Translating the biology of diffuse large B-cell lymphoma into treatment
    Review

    Danilov, A. V.; Magagnoli, M.; Matasar, M. J.
    The Oncologist (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma
    Journal Article

    Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trnĕný, M.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; Matasar, M.; Rai, S.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save